Novo says patients looked about two to three years younger on proteomic clocks across 10,052 people. Aging clock pioneer Steve Horvath calls it a strong effect.
Recap by typeshit. Full story at MIT Technology Review.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Lofton calls the Phase 3 retatrutide results she has seen impressive and notes the drug is drawing a lot of attention right now.
A short podcast clip with Terry Dubrow talks up retatrutide's commercial potential. Little detail beyond the bold money claim.
Loading…